MX2020008126A - Compuesto de amida heterociclica nitrogenada y su uso para fines medicos. - Google Patents
Compuesto de amida heterociclica nitrogenada y su uso para fines medicos.Info
- Publication number
- MX2020008126A MX2020008126A MX2020008126A MX2020008126A MX2020008126A MX 2020008126 A MX2020008126 A MX 2020008126A MX 2020008126 A MX2020008126 A MX 2020008126A MX 2020008126 A MX2020008126 A MX 2020008126A MX 2020008126 A MX2020008126 A MX 2020008126A
- Authority
- MX
- Mexico
- Prior art keywords
- diabetes
- disease
- heart failure
- type
- amide compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/99—Enzyme inactivation by chemical treatment
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
Abstract
La presente invencion proporciona un compuesto que tiene actividad inhibidora de PDHK y util para el tratamiento o profilaxis de diabetes (diabetes tipo 1, diabetes tipo 2 etc.), sindrome de resistencia a la insulina, sindrome metabolico, hiperglucemia, hiperlactacidemia, complicaciones diabeticas (neuropatía diabetica, retinopatia diabetica, nefropatia diabetica, catarata etc.), insuficiencia cardiaca (insuficiencia cardiaca aguda, insuficiencia cardiaca cronica), cardiomiopatia, isquemia miocardica, infarto de miocardio, angina de pecho, dislipidemia, aterosclerosis, enfermedad arterial periferica, claudicacion intermitente, enfermedad pulmonar obstructiva cronica, isquemia cerebral, apoplejia cerebral, enfermedad mitocondrial, encefalomiopatia mitocondrial, cancer, hipertension pulmonar o enfermedad de Alzheimer; la presente invencion se refiere a un compuesto de la formula [I-a] o la formula [II], o una de sus sales farmaceuticamente aceptables: (ver formula) donde cada simbolo significa lo mismo como se describe en la memoria descriptiva.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018016328 | 2018-02-01 | ||
| PCT/JP2019/003052 WO2019151274A1 (ja) | 2018-02-01 | 2019-01-30 | 含窒素複素環アミド化合物及びその医薬用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020008126A true MX2020008126A (es) | 2020-09-18 |
Family
ID=67479787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020008126A MX2020008126A (es) | 2018-02-01 | 2019-01-30 | Compuesto de amida heterociclica nitrogenada y su uso para fines medicos. |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US10800784B2 (es) |
| EP (1) | EP3747888A4 (es) |
| JP (3) | JP7241556B2 (es) |
| KR (1) | KR102725118B1 (es) |
| CN (1) | CN111655692B (es) |
| AR (1) | AR114237A1 (es) |
| AU (1) | AU2019214048B2 (es) |
| BR (1) | BR112020014177A2 (es) |
| CA (1) | CA3090219A1 (es) |
| CL (1) | CL2020002003A1 (es) |
| CO (1) | CO2020009420A2 (es) |
| IL (1) | IL276386B2 (es) |
| MX (1) | MX2020008126A (es) |
| MY (1) | MY205011A (es) |
| PE (1) | PE20211273A1 (es) |
| PH (1) | PH12020500613A1 (es) |
| SA (1) | SA520412473B1 (es) |
| SG (1) | SG11202006916SA (es) |
| TW (1) | TWI803570B (es) |
| WO (1) | WO2019151274A1 (es) |
| ZA (1) | ZA202004548B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112638377A (zh) | 2018-09-11 | 2021-04-09 | 日本烟草产业株式会社 | 含有吡唑酰胺化合物的慢性肾脏病的治疗或预防剂 |
| CN110407744A (zh) * | 2019-08-13 | 2019-11-05 | 上海毕得医药科技有限公司 | 一种1-(4-氨基吡啶-2-基)乙酮的合成方法 |
| EP4458834A3 (en) | 2020-02-07 | 2025-01-15 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| KR20220149688A (ko) * | 2020-03-04 | 2022-11-08 | 니뽄 다바코 산교 가부시키가이샤 | 축합 3환성 화합물 및 그의 의약 용도 |
| WO2022052958A1 (en) * | 2020-09-10 | 2022-03-17 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| JP7599039B2 (ja) * | 2021-03-23 | 2024-12-12 | 上海海雁医薬科技有限公司 | 複素環置換ケトン類誘導体、その組成物および医薬における使用 |
| AR126913A1 (es) | 2021-09-01 | 2023-11-29 | Japan Tobacco Inc | Compuesto tricíclico que contiene nitrógeno y su uso farmacéutico |
| WO2024169952A1 (en) | 2023-02-16 | 2024-08-22 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7943617B2 (en) * | 2006-11-27 | 2011-05-17 | Bristol-Myers Squibb Company | Heterobicyclic compounds useful as kinase inhibitors |
| WO2008132162A1 (en) | 2007-04-26 | 2008-11-06 | Boehringer Ingelheim International Gmbh | 3- (sulphonylamino) -phenyl-2 -hydroxy-ethylamino derivatives useful as beta-agonists, processes for preparing them and their use as medicaments |
| WO2008153792A2 (en) * | 2007-06-01 | 2008-12-18 | Schering Corporation | Gamma secretase modulators |
| EP2090576A1 (en) * | 2008-02-01 | 2009-08-19 | Merz Pharma GmbH & Co.KGaA | 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators |
| AR074797A1 (es) * | 2008-10-10 | 2011-02-16 | Japan Tobacco Inc | Compuesto de fluoreno , composiciones farmaceuticas , inhibidores de pdhk y pdhk2 , metodos de tratamiento , usos de los mismos y kit comercial |
| WO2013000084A1 (en) | 2011-06-27 | 2013-01-03 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| CA2855009C (en) | 2011-11-15 | 2019-07-09 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds useful as gpr119 agonists |
| PT2858986T (pt) | 2012-06-12 | 2019-11-29 | Chong Kun Dang Pharmaceutical Corp | Derivados de piperidina como agonistas de gpr119 |
| CN103570725B (zh) | 2012-08-01 | 2017-03-22 | 中国科学院上海药物研究所 | 哌嗪并三唑类化合物及其制备方法和用途 |
| EP2975028B1 (en) * | 2013-03-15 | 2018-02-21 | Japan Tobacco, Inc. | Pyrazole-amide compound and medicinal uses therefor |
| WO2015002118A1 (ja) * | 2013-07-01 | 2015-01-08 | 日本たばこ産業株式会社 | フルオレン－アミド化合物およびその医薬用途 |
| WO2015002119A1 (ja) | 2013-07-01 | 2015-01-08 | 日本たばこ産業株式会社 | ピラゾール－アルコール化合物およびその医薬用途 |
| GB201316823D0 (en) * | 2013-09-23 | 2013-11-06 | R & D Vernalis Ltd | New Chemical Entities |
| MX2016007810A (es) | 2013-12-17 | 2016-09-07 | Merck Patent Gmbh | Derivados de n1-(3,3,3-trifluoro-2-hidroxo-2-metilpropionil)-piper idina como inhibidores de piruvato deshidrogenasa cinasa. |
| JP6847942B2 (ja) * | 2015-07-31 | 2021-03-24 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 二環式複素環式誘導体 |
| ES2797301T3 (es) | 2016-03-29 | 2020-12-01 | Merck Patent Gmbh | Derivados de piperidinil-propanona |
| CN109071490B (zh) * | 2016-04-28 | 2021-04-06 | 默克专利股份公司 | 哌啶基衍生物 |
| MX2019001228A (es) * | 2016-07-29 | 2019-06-03 | Japan Tobacco Inc | Metodo de produccion del compuesto de pirazol-amida. |
| US10414774B2 (en) | 2016-08-15 | 2019-09-17 | Merck Sharp & Dohme Corp. | Compound useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolc disease |
| WO2018078042A1 (en) | 2016-10-28 | 2018-05-03 | H. Lundbeck A/S | Combination treatments comprising administration of imidazopyrazinones |
| KR20190075068A (ko) | 2016-10-28 | 2019-06-28 | 하. 룬드벡 아크티에셀스카브 | 정신 및/또는 인지 장애의 치료를 위한 이미다조피라지논을 포함하는 병용 치료 |
| KR20220149688A (ko) * | 2020-03-04 | 2022-11-08 | 니뽄 다바코 산교 가부시키가이샤 | 축합 3환성 화합물 및 그의 의약 용도 |
| AR126913A1 (es) * | 2021-09-01 | 2023-11-29 | Japan Tobacco Inc | Compuesto tricíclico que contiene nitrógeno y su uso farmacéutico |
-
2019
- 2019-01-30 MY MYPI2020003575A patent/MY205011A/en unknown
- 2019-01-30 MX MX2020008126A patent/MX2020008126A/es unknown
- 2019-01-30 KR KR1020207024426A patent/KR102725118B1/ko active Active
- 2019-01-30 US US16/261,792 patent/US10800784B2/en active Active
- 2019-01-30 PE PE2020001125A patent/PE20211273A1/es unknown
- 2019-01-30 CA CA3090219A patent/CA3090219A1/en active Pending
- 2019-01-30 TW TW108103504A patent/TWI803570B/zh active
- 2019-01-30 CN CN201980010396.9A patent/CN111655692B/zh active Active
- 2019-01-30 AU AU2019214048A patent/AU2019214048B2/en active Active
- 2019-01-30 EP EP19747660.9A patent/EP3747888A4/en active Pending
- 2019-01-30 SG SG11202006916SA patent/SG11202006916SA/en unknown
- 2019-01-30 BR BR112020014177-1A patent/BR112020014177A2/pt unknown
- 2019-01-30 WO PCT/JP2019/003052 patent/WO2019151274A1/ja active IP Right Grant
- 2019-01-30 JP JP2019013745A patent/JP7241556B2/ja active Active
- 2019-01-30 AR ARP190100202A patent/AR114237A1/es unknown
-
2020
- 2020-07-14 PH PH12020500613A patent/PH12020500613A1/en unknown
- 2020-07-21 SA SA520412473A patent/SA520412473B1/ar unknown
- 2020-07-22 ZA ZA2020/04548A patent/ZA202004548B/en unknown
- 2020-07-29 IL IL276386A patent/IL276386B2/en unknown
- 2020-07-29 CO CONC2020/0009420A patent/CO2020009420A2/es unknown
- 2020-07-30 CL CL2020002003A patent/CL2020002003A1/es unknown
- 2020-10-08 US US17/065,679 patent/US20210284644A1/en not_active Abandoned
-
2023
- 2023-03-07 JP JP2023034806A patent/JP2023071925A/ja not_active Ceased
- 2023-09-05 US US18/460,821 patent/US20240300952A1/en not_active Abandoned
-
2024
- 2024-06-12 JP JP2024094812A patent/JP2024116307A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020500613A1 (en) | Nitrogenated heterocyclic amide compound, and use thereof for medical purposes | |
| RU2015144182A (ru) | Пиразоламидное соединение и его применения в медицине | |
| ZA202209620B (en) | Fused tricyclic compound and medicinal use thereof | |
| CY1125006T1 (el) | Λιπαρα οξεα και η χρηση τους σε συνδυασμο με βιομορια | |
| JP2008532974A5 (es) | ||
| JP2019131544A5 (es) | ||
| JP2014518853A5 (es) | ||
| HRP20230633T1 (hr) | Supstituirani 2-azabicikli i njihova uporaba kao modulatora receptora oreksina | |
| NO20084919L (no) | Oksadiazolidindionforbindelse | |
| PE20110804A1 (es) | Compuestos novedosos como ligandos de receptores de cannabinoides | |
| AR074619A1 (es) | Derivados de ciclopentilacrilamida | |
| EA202190302A1 (ru) | Соединения 2,6-диаминопиридина | |
| JP2016519106A5 (es) | ||
| RU2007103303A (ru) | Производные пиримидина | |
| CO2024003629A2 (es) | Compuesto tricíclico que contiene nitrógeno y su uso farmacéutico | |
| JP2018513846A5 (es) | ||
| ZA202402435B (en) | Nitrogen-containing tricyclic compound and pharmaceutical use thereof | |
| EA201892687A1 (ru) | Кристаллическая форма соединения, подавляющего активность протеинкиназы, и её применение | |
| EA201391314A1 (ru) | Новое фенилпиридиновое производное и содержащее его лекарственное средство | |
| RU2018128304A (ru) | Пиразоламидное соединение и его применения в медицине | |
| RU2018131500A (ru) | Кристаллические модификации гидрохлорида n-(4,5-бисметансульфонил-2-метилбензоил)гуанидина и солей n-(4,5-бисметансульфонил-2-метилбензоил)гуанидина | |
| NZ610866A (en) | Diphenyl sulfide derivative and pharmaceutical product which contains same as active ingredient | |
| JP2019523253A5 (es) | ||
| HRP20130983T1 (hr) | Derivati arilciklopropilacetamida, korisni kao aktivatori glukokinaze | |
| NZ774406B2 (en) | 2,6-diamino pyridine compounds |